Sen. Amy Klobuchar (D-Minn.) discusses legislation for EpiPen-like generic drugs to be more widely available, pricing controls and drug importation from Canada.
Sen. Amy Klobuchar (D-Minn.) discusses Mylan CEO Heather Bresch's comments on the EpiPen pricing controversy.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
Hedge fund Pershing Square Capital Management sold its entire stake of 9.8 million shares, The New York Times reports.
Herbalife is saying after two years of working with the FTC, the company understands the terms of the settlement, reports CNBC's Scott Wapner.
The "FMHR" traders and John Spallanzani, GFI Group Chief Macro Strategist, discuss Ackman's response to the FTC Herbalife settlement.
Robert Chapman, Chapman Capital, comments on Herbalife's $200M agreement with FTC, as well as his views on the future of its stock.
Tim Ramey, Pivotal Research Analyst, comments on the $200M Herbalife settlement with FTC.
FTC Chairwoman Edith Ramirez announces the settlement with Herbalife. CNBC's David Faber provides perspective.
Carl Icahn, Herbalife's largest shareholder releases a statement after the FTC announces it reached a $200 million settlement with Herbalife.
The FTC and Herbalife have reached an agreement, reports CNBC's Scott Wapner.
Walgreens' Pessina estimates that the combined company will have to sell roughly 500 stores in order to gain regulatory approval from the FTC.
Shares of Walgreens and Rite Aid skyrocketed around 4 percent amid reports that the FTC is likely to approve Walgreens' acquisition of Rite Aid.
The court did the right thing by shredding the Staples-Office Depot deal, a former FTC commissioner said Wednesday.
CNBC's Dominic Chu looks at shares of Alphabet after a report from Politico saying the FTC could take a second look into Google's search dominance.
Frank Aquila, Sullivan & Cromwell Partner and Mergers & Acquisition Attorney, speaks about the climate for M&A and why so many deals have been blocked recently.
Former FTC Commissioner Julie Brill weighs in on the Federal Trade Commission stopping a deal between Office Depot and Staples for antitrust reasons as well as the state of M&A activity in the U.S.
Staples and Office Depot became the latest companies to abandon plans for a merger after facing scrutiny on antitrust grounds.
U.S. authorities have asked mobile phone carriers and manufacturers including Apple and Samsung, to explain how they release security updates.